| HOME >> MEDICINE >> TECHNOLOGY |
17,59117,08917,49216,909Diluted
18,14517,96518,16917,892GENOPTIX, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)September 30,
2010 December 31,
2009 (unaudited) AssetsCurrent assets: Cash and cash equivalents
$
20,068$
27,945 Short-term investment securities
118,503113,049 Accounts receivable, net
35,80127,707 Income tax receivable
1,598- Deferred tax asset
5,4065,406 Other current assets
3,3913,320Total current assets
184,767177,427Property and equipment, net
37,36113,826Restricted cash
180270Long-term investment security
4,5243,786Long-term deferred tax asset
1,5251,800Other long-term assets
1,824346Total assets
$
230,181$ 197,455Liabilities and Stockholders' EquityCurrent liabilities: Accounts payable and accrued expenses
$
8,759$
8,322 Accrued compensation
7,7334,667 Income tax payable
1,4171,557 Deferred revenues
1,4541,225 Deferred rent
306331Total current liabilities
19,66916,102Long-term deferred rent
1,7221,732Other long-term liabilities
101117Stockholders' equity:Preferred stock
--Common stock
1817Additional paid-in capital
173,468160,064Treasury stock
(68)(25)Accumulated other comprehensive loss
(65)(546)Retained earnings
35,33619,994Total stockholders' equity
208,689179,504Total liabilities and stockholders' equity
$
230,181$ 197,455GENOPTIX, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(unaudited)(in thousands)Nine Months Ended
September 30, 2010 2009 Operating activities:Net income
$
5,342$
23,278Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization
3,2012,583Provision for doubtful accounts
3,9632,240Stock-based compensation expense
9,5417,306Excess tax bene
'/>"/>
| SOURCE Genoptix, Inc. Copyright©2010 PR Newswire. All rights reserved |